(Q40635053)

22 September 2017

title

Considerations to the policy of future clinical therapeutic trials in DMD. (English)

1 reference

22 September 2017

Bernd Reitter

1

1 reference

22 September 2017

language of work or name

1 reference

1 October 2002

1 reference

22 September 2017

published in

Neuromuscular Disorders

1 reference

22 September 2017

volume

12 Suppl 1

1 reference

22 September 2017

page(s)

S166-8

1 reference

Clinical trial in Duchenne dystrophy. I. The design of the protocol

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900096-2

7 January 2021

Clinical investigation in duchenne dystrophy: 2. Determination of the ?power? of therapeutic trials based on the natural history

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900096-2

7 January 2021

Functional evaluation of Duchenne muscular dystrophy: proposal for a protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900096-2

7 January 2021

Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900096-2

7 January 2021

Long-term benefit from prednisone therapy in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900096-2

7 January 2021

Prednisone in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900096-2

7 January 2021

Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900096-2

7 January 2021

A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900096-2

7 January 2021

Preserving function in Duchenne dystrophy with long-term pulse prednisone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900096-2

7 January 2021

Steroids in duchenne muscular dystrophy — Deflazacort trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900096-2

7 January 2021

Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900096-2

7 January 2021

A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900096-2

7 January 2021

The conduct and principles of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900096-2

7 January 2021

Pre-clinical screening of drugs using the mdx mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900096-2

7 January 2021

Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900096-2

7 January 2021

Clinical investigation of Duchenne muscular dystrophy. A methodology for therapeutic trials based on natural history controls

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900096-2

7 January 2021

10.1016/S0960-8966(02)00096-2

Identifiers

DOI

1 reference

22 September 2017

1 reference